Evidence map›Paper›PMID 37924384›Full record

ArticleDiscover oncology2023

Association between testosterone and cancers risk in women: a two-sample Mendelian randomization study.

Zhizhou Li, Maoyu Wang, Meimian Hua, Ziwei Wang, Yidie Ying, Zhensheng Zhang, Shuxiong Zeng, Huiqing Wang, Chuanliang Xu

Open access · goldAbstract read
In one paragraph

Article in Discover oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.8field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Zhizhou Li *Department of Urology, Shanghai Changhai Hospital, Naval Medical University, Shanghai, China.
Maoyu Wang *Department of Urology, Shanghai Changhai Hospital, Naval Medical University, Shanghai, China.
Meimian Hua *Department of Urology, Shanghai Changhai Hospital, Naval Medical University, Shanghai, China.
Ziwei WangDepartment of Urology, Shanghai Changhai Hospital, Naval Medical University, Shanghai, China.
Yidie YingDepartment of Urology, Shanghai Changhai Hospital, Naval Medical University, Shanghai, China.
Zhensheng ZhangDepartment of Urology, Shanghai Changhai Hospital, Naval Medical University, Shanghai, China.
Shuxiong ZengDepartment of Urology, Shanghai Changhai Hospital, Naval Medical University, Shanghai, China. zengshuxiong@126.com.
Huiqing WangDepartment of Urology, Shanghai Changhai Hospital, Naval Medical University, Shanghai, China. WHQLLL@126.com.
Chuanliang XuDepartment of Urology, Shanghai Changhai Hospital, Naval Medical University, Shanghai, China. chuanliang_xu@126.com.
Second Military Medical University · CNChanghai Hospital · CN

Funding

National Natural Science Foundation of China 81772720National Natural Science Foundation of China 82172871The "234 Disciplines Peak Climbing Plan" Fund of the Naval Medical University 2020YXK019The "Voyaging Talents" Fund of the Naval Medical University 2021008149
6 · The paper itself

Abstract

objectivePrevious observational studies have explored the correlation between testosterone and cancer risk. However, the causal association between testosterone and various cancer types in women remains inconclusive. The objective of this Mendelian randomization study is to evaluate the causal links between total testosterone (TT) and bioavailable testosterone (BT) with cancer risk in females.

methodsInitially, a rigorous quality control process was employed to identify suitable instrumental single nucleotide polymorphisms (SNPs) associated with the exposure under investigation that exhibited a significant association. The genetic causal relationship between female testosterone levels and the risk of developing cancers was examined through a two-sample Mendelian randomization. Various analytical methods, including inverse-variance weighted (IVW), MR-Egger, weighted median, simple mode, and weighted mode, were applied in the investigation. Key findings were primarily based on the results obtained via IVW (random effects), and sensitivity analyses were conducted to assess the reliability of the obtained results. Furthermore, maximum likelihood, penalized weighted median, and IVW (fixed effects) methods were utilized to further validate the robustness of the results.

resultsBased on the results of IVW analysis, our study indicated a positive causal relationship between BT and breast cancer (OR = 1.1407, 95%CI: 1.0627-1.2244, P = 0.0015) and endometrial cancer (OR = 1.4610, 95%CI: 1.2695-1.6813, P = 1.22E-06). Moreover, our findings also showed a positive causal association between TT and breast cancer (OR = 1.1764, 95%CI: 1.0846-1.2761, P = 0.0005), cervical cancer(OR = 1.0020, 95%CI: 1.0007-1.0032, P = 0.0077), and endometrial cancer(OR = 1.4124, 95%CI: 1.2083-1.6511, P = 0.0001). Additionally, our results demonstrated a negative causal relationship between BT and ovarian cancer (OR = 0.8649, 95%CI: 0.7750-0.9653, P = 0.0320). However, no causal relationship was found between BT, TT and other types of cancer (corrected P > 0.05).

conclusionsThis study elucidates the role of testosterone on the development of breast cancer, endometrial cancer, ovarian cancer, and cervical cancer. It also hints at a potential but fragile link between testosterone and bladder cancer, as well as thyroid cancer. Nonetheless, it's worth noting that no statistically significant relationship between testosterone and various other types of cancer in females was identified.

Indexed as

Bioavailable testosteroneCancerFemaleMendelian randomizationTestosterone

Identifiers

PMID37924384
PMCPMC10625503
OpenAlexW4388339702

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.